← ANALYST RATINGS · TIPRANKS
Vaxcyte (PCVX): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy1 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $117, the highest $163, the lowest $75.00. The average is +84.4% from the last price of $63.62.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $69.00 → $67.00−2.9% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $67.00 → $66.00−1.5% | Hold | +3.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $68.00 → $66.00−2.9% | Hold | +3.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $67.00 → $66.00−1.5% | Hold | +3.7% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $72.00 → $71.00−1.4% | Buy | +11.6% | Upgrade | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $66.00 → $65.00−1.5% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $120 | Buy | +88.6% | Reiterated | 12.10.26on TipRanks 08:20 | −1.0%next day −5.4% | ↗ |
| Unknown Analyst | Leerink Partners | $82.00 → $102+24.4% | Buy | +60.3% | Reiterated | 09.10.26on TipRanks Oct 10 02:05 | +9.2%next day −1.0% · 5 days −8.9% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $67.00 → $85.00+26.9% | Hold | +33.6% | Reiterated | 06.10.26on TipRanks Oct 7 08:31 | −10.2%next day +0.6% · 5 days +0.3% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $130 → $146+12.3% | Buy | +129.5% | Reiterated | 05.10.26on TipRanks Oct 6 06:30 | +30.0%next day −10.2% · 5 days −4.7% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $110 → $122+10.9% | Buy | +91.8% | Assigned | 05.10.26on TipRanks 13:30 | +30.0%next day −10.2% · 5 days −4.7% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $146 | Buy | +129.5% | Reiterated | 05.10.26on TipRanks 10:00 | +30.0%next day −10.2% · 5 days −4.7% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $163 | Buy | +156.2% | Reiterated | 05.10.26on TipRanks 09:55 | +30.0%next day −10.2% · 5 days −4.7% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $116 → $125+7.8% | Buy | +96.5% | Reiterated | 05.10.26on TipRanks 07:16 | +30.0%next day −10.2% · 5 days −4.7% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $75.00 | Buy | +17.9% | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | +2.4%next day +5.5% · 5 days +6.3% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $89.00 | Buy | +39.9% | Reiterated | 29.07.26on TipRanks Jul 30 06:15 | −1.4%next day +3.9% · 5 days 0.0% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Reiterated | 21.05.26on TipRanks 09:45 | +0.3%next day −0.6% · 5 days +6.6% | ↗ |
| Unknown Analyst | Jefferies | $146 | Buy | +129.5% | Reiterated | 25.02.26on TipRanks 13:15 | +1.9%next day −4.3% · 5 days −3.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vaxcyte
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $97.50 at a price of $56.90 (+71.4%); now: $117 at $63.62 (+84.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 7 | 8 | 9 | 6 | 10 |
| Buy | 4 | 3 | 3 | 1 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.11 (from $-2.68 to $-1.67). Last quarter: $-1.97.
Best top-analyst consensus in the sector · Healthcare
About Vaxcyte
- CEO: Grant E. Pickering
- Employees: 507
- 825 Industrial Road, San Carlos, CA, 94070, US
- vaxcyte.com
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Data from the stock’s TipRanks forecast page, read 65 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗